Market Research Logo

Conference Documentation: Allergies

Allergies are currently skyrocketing. In this current day and age it is reckoned that one in five people have an allergy.

Previously there had been very little knowledge of what caused allergies and how to combat them. The aversion strategy had been the main form of attack against the prevalence of an adverse immune attack. However, this has seemingly not been the best approach.
Immunotherapy techniques have been developed to wean the body to accepting immunogenic samples by queuing the response to them and sensitising the body to the exposure of allergens. The field is very much in its infancy with a range of exciting discoveries giving hope to people suffering from allergies.

However, there is a great lack of understanding on matters of how to administer therapy in an effective manner and how to increase patient compliance.

The second annual Allergies conference takes place on the 8th-9th of July 2015 at the Marriott Regents Park, London and will introduce the audience to a range of new developments in the field and allow for an understanding of where the field of allergy therapeutics is going.
The agenda focuses on a range of hot topics:

Development of novel vaccines and adjuvants for immunotherapy
Regulation and clinical trials for paediatric immunotherapy to allow for a strong understanding of the current requirements and obligations in the development of immunotherapy products.
Increasing patient compliance and increasing the quality of life for the patients that are being treated on a day to day basis with therapeutics.
Personalised medicines for the treatment of specific phenotypes rather than taking the one fits all strategy.
New pathways will be discussed and elaborated to allow for new targeting strategies to be developed.

Join us and hear expert opinions on these and many more topics in the field of Allergy therapeutics.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Adam Chaker, Munich Allergy Research Centre, Klinikum rechts der Isar, Technische Universität München
9:10
Challenges in the development of allergen immunotherapies
Rod Hafner, Senior Vice President Research and Development, Circassia Ltd
9:50
Specific Immunotherapy under the umbrella of anti IL-4: a new perspective for patients?
Adam Chaker, Munich Allergy Research Centre, Klinikum rechts der Isar, Technische Universität München
10:30
Morning Coffee
11:00
Oral Mucosal Immunotherapy (OMIT): A new approach to delivering allergen-specific immunotherapy
Erick Berglund, CEO, Allovate
11:40
Epicutaneous immunotherapy, a new treatment in life threatening food allergies
Pierre-Henri Benhamou, CEO, DBV Technologies
12:20
Networking Lunch
13:30
Formulation and delivery of state of the art allergy therapeutics
Tim Higenbottam, Research & Development Director, Allergy Therapeutics Ltd
14:10
Paediatric trials with specific immunotherapy
Angelika Sager , Medical director , Leti Laboratories
14:50
Afternoon Tea
15:20
Confirmatory trials – is a field study still the gold standard?
Diderik Boot, Medical Director, HAL-Allergy
16:00
Increasing probability of success in allergy clinical trials
Juan Gispert, Senior medical director. European Head Allergy, Respiratory, Infectious Diseases and Vaccines, Quintiles
16:40
Chairman's Closing Remarks and Close of Day Two
Adam Chaker, Munich Allergy Research Centre, Klinikum rechts der Isar, Technische Universität München
Day 2
8:30
Registration & Coffee
9:00
Morning Chairman's Opening Remarks
Ian Strickland, Research Scientist, MedImmune
9:10
Advances in the field of Atopic Dermatitis
Ian Strickland, Research Scientist, MedImmune
9:50
Sublingual Immunotherapy vs Sub cutaneous immunotherapy
Guy Scadding, Specialist registrar, Royal Brompton Hospital
10:30
Morning Coffee
11:00
Safety data management in the field of allergy therapeutics
Inmaculada Cerecedo, Medical Advisor, Laboratorios Leti
11:40
LAMB-Dx – A Novel Approach To Food And Respiratory Allergy Diagnosis Through The Detection Of Local IgE
Kate Rochlin, CSO, Immunovent
12:20
Networking Lunch
13:20
Afternoon Chairman's Opening Remarks
Tracy Hussell, Centre Director MCCIR, Manchester University
13:30
Novel anti-inflammatory agents in immune-mediated ocular diseases
Virginia Calder, Senior Lecturer, UCL
14:10
Alternaria-derived serine protease: a novel pathway for asthma exacerbations mapped
Clare Lloyd, Professor of Respiratory Immunology, Imperial College London
14:50
Afternoon Tea
15:20
Identification of a new target to eliminate Th2 memory cells
Philip Ashton-Rickardt, Professor of Immunology, Imperial College London
16:00
Testing new uncharted pathways involved in Asthma
Tracy Hussell, Centre Director MCCIR, Manchester University
16:40
Involvement in Clinical Trials, the Patients Perspective
Lynne Regent, CEO, Anaphylaxis Campaign
17:20
Environmental Exposure Chambers for Use in Pivotal Allergy Trials
Anne Marie Salapatek, President & Chief Scientific Officer, Inflamax Research, Inc.
18:00
Chairman’s Closing Remarks and Close of Day Two
Tracy Hussell, Centre Director MCCIR, Manchester University

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report